MedTrace Logo

ImPROving Quality of LIFe in the Long COVID Patient

NCT05823896 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2024-12-04

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy of orally administered nirmatrelvir/ritonavir compared with placebo/ritonavir to improve quality of life in non-hospitalized adult participants suffering from post-acute COVID-19 syndrome.

Conditions

  • Post-COVID-19 Syndrome
  • Long COVID
  • Long Covid19
  • COVID-19
  • POTS - Postural Orthostatic Tachycardia Syndrome
  • Post COVID-19 Condition
  • Post-COVID Syndrome
  • Post COVID-19 Condition, Unspecified
  • Postinfectious Inflammation
  • Postinfectious Disorder

Interventions

DRUG

Nirmatrelvir/ritonavir

300/100 mg tablet twice daily (q12h) administered orally for 15 days

DRUG

Placebo/ritonavir

100mg tablet twice daily (q12h) administered orally for 15 days

Sponsors & Collaborators

Principal Investigators

  • Michael Runold, MD, PhD · Karolinska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2024-11-28
Completion
2024-11-28
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05823896 on ClinicalTrials.gov